Printer Friendly

ONCOGENE SCIENCE REPORTS FIRST QUARTER RESULTS

 ONCOGENE SCIENCE REPORTS FIRST QUARTER RESULTS
 UNIONDALE, N.Y., Feb. 7 /PRNewswire/ -- Oncogene Science, Inc.


(NASDAQ: ONCS), today announced revenues of $2,211,251 for the first quarter ending Dec. 31, 1991, an increase of 30 percent from the $1,700,105 reported for the first quarter last year. The company had a net loss of $979,495, or $(.07) per share, compared to a net loss of $209,658, $(.02) per share, for the same period last year.
 Commenting on the first quarter results, Gary E. Frashier, president and chief executive officer, said "The increase in revenue is a result of continuing increases in sales of our research products as well as the start of our collaboration with Becton Dickinson to develop cancer diagnostics. Our product sales were approximately $911,000 for the quarter representing an increase of 37 percent over the same quarter of the previous year. Much of the increase in our net loss is attributable to amortization of intangible assets relating to our acquisition of Applied BioTechnology, Inc. as well as the start up of the cancer diagnostics research program.
 "We are very pleased with the collaboration between the company and American Home Products which was entered into in December, and that it is now underway."
 Oncogene Science, Inc., using proprietary oncogene-related and growth factor technologies, is in the business of developing biopharmaceutical products for the research, diagnosis and treatment of cancer and other cell control-linked diseases.
 ONCOGENE SCIENCE, INC.
 SELECTED FINANCIAL DATA
 Three months ended Dec. 31 1991 1990
 Revenues $2,211,251 $1,700,105
 Net loss (979,495) (209,658)
 Loss per share (.07) (.02)
 -0- 2/7/92
 /CONTACT: Robert L. Van Nostrand, vice president-finance and administration of Oncogene Science, 516-365-9300, or Susan Noonan of Noonan/Russo Communications, 212-979-9180, for Oncogene Science/
 (ONCS) CO: Oncogene Science, Inc. ST: New York IN: MTC SU: ERN


SH-OS -- NY061 -- 7866 02/07/92 15:15 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 7, 1992
Words:321
Previous Article:WABASH NATIONAL CORPORATION ANNOUNCES SALE OF 2 MILLION SHARES BY PRINCIPAL HOLDERS
Next Article:SECRETARY OF ENERGY WATKINS PRAISES SUCCESS OF COMPREHENSIVE ENERGY LEGISLATION TO DATE
Topics:


Related Articles
ONCOGENE SCIENCE, INC. REPORTS FOURTH QUARTER AND YEAR-END RESULTS
ONCOGENE SCIENCE, CIBA-GEIGY AND PFIZER INK PACT FOR PRODUCTION, DEVELOPMENT AND MARKETING OF PROTEIN-BASED DRUG
ONCOGENE SCIENCE ISSUED PATENT FOR RAS ONCOGENE
ONCOGENE SCIENCE ISSUED PATENT FOR TGF BETA-3
ONCOGENE SCIENCE AND PFIZER EXTEND CANCER COLLABORATION FOR ADDITIONAL FIVE YEARS
ONCOGENE SCIENCE EXPANDS DRUG DISCOVERY CAPABILITY WITH ACQUISITION OF MYCOSEARCH, INC.
ONCOGENE SCIENCE, INC. RECEIVES SBIR PHASE II GRANT FOR HIV-1 RESEARCH
Oncogene Science, Inc. Reports First Quarter Results
Oncogene Science and Hoechst Marion Roussel Form Collaboration To Develop Small Molecule Compounds to Treat Chronic Anemias
CN Biosciences, Inc. Reports Third Quarter 1998 Financial Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters